Hvad angår de sikkerhedsmæssige betænkeligheder omkring tilfældene af maligne lidelser konkluderede CHMP, at der i produktoplysningerne bør Læ
In order to address the safety concerns in relation to the cases of malignancies the CHMP concluded that warnings reflecting the cases of malignancies and the need for monitoring of patients treated with Protopy should be included in the product information.